SG11201811223YA - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
SG11201811223YA
SG11201811223YA SG11201811223YA SG11201811223YA SG11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA SG 11201811223Y A SG11201811223Y A SG 11201811223YA
Authority
SG
Singapore
Prior art keywords
international
pct
yield
publication
date
Prior art date
Application number
SG11201811223YA
Other languages
English (en)
Inventor
Corswant Christian Von
Romain Bordes
Jonasson Simon Hjelm
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SG11201811223YA publication Critical patent/SG11201811223YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
SG11201811223YA 2016-07-08 2017-07-06 Pharmaceutical compositions SG11201811223YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1611920.8A GB201611920D0 (en) 2016-07-08 2016-07-08 Pharmaceutical compositions
PCT/EP2017/066983 WO2018015175A1 (en) 2016-07-08 2017-07-06 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
SG11201811223YA true SG11201811223YA (en) 2019-01-30

Family

ID=56890842

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811223YA SG11201811223YA (en) 2016-07-08 2017-07-06 Pharmaceutical compositions

Country Status (20)

Country Link
US (1) US20200254046A1 (enExample)
EP (1) EP3481377A1 (enExample)
JP (1) JP2019520393A (enExample)
KR (1) KR20190026816A (enExample)
CN (1) CN109414409A (enExample)
AU (1) AU2017298873B2 (enExample)
BR (1) BR112019000240A2 (enExample)
CA (1) CA3029331A1 (enExample)
CL (1) CL2019000042A1 (enExample)
CO (1) CO2019000083A2 (enExample)
CR (1) CR20190007A (enExample)
DO (1) DOP2019000002A (enExample)
EA (1) EA201990162A1 (enExample)
GB (1) GB201611920D0 (enExample)
IL (1) IL263999A (enExample)
MX (1) MX2019000255A (enExample)
PE (1) PE20190321A1 (enExample)
PH (1) PH12019500024A1 (enExample)
SG (1) SG11201811223YA (enExample)
WO (1) WO2018015175A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022071463A1 (ja) * 2020-10-02 2022-04-07 住友精化株式会社 粘性組成物
JPWO2022071461A1 (enExample) * 2020-10-02 2022-04-07

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378444B2 (en) * 2002-06-17 2008-05-27 Brigham And Women's Hospital, Inc. Analogues of lipid mediators derived from omega-3 PUFAs and methods of use
WO2008145183A1 (en) * 2007-05-30 2008-12-04 Nestec S.A. Oil-in-water emulsion and its use for the delayed release of active elements
GB2465988A (en) * 2008-12-03 2010-06-09 Omegatri As Powder or tablet containing unsaturated fatty acid and water insoluble carbohydrate
CN102421422A (zh) * 2009-03-09 2012-04-18 普罗诺瓦生物医药挪威公司 含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
CN102512664B (zh) * 2010-12-31 2015-04-01 舒泰神(北京)生物制药股份有限公司 一种神经生长因子组合物
CN107050457A (zh) 2012-01-06 2017-08-18 翁特拉制药公司 游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物

Also Published As

Publication number Publication date
IL263999A (en) 2019-01-31
CN109414409A (zh) 2019-03-01
JP2019520393A (ja) 2019-07-18
CA3029331A1 (en) 2018-01-25
KR20190026816A (ko) 2019-03-13
GB201611920D0 (en) 2016-08-24
AU2017298873B2 (en) 2020-04-30
EP3481377A1 (en) 2019-05-15
CO2019000083A2 (es) 2019-01-18
PH12019500024A1 (en) 2019-11-04
EA201990162A1 (ru) 2019-06-28
WO2018015175A1 (en) 2018-01-25
PE20190321A1 (es) 2019-03-04
CR20190007A (es) 2019-03-05
US20200254046A1 (en) 2020-08-13
WO2018015175A9 (en) 2018-03-29
MX2019000255A (es) 2019-05-27
AU2017298873A1 (en) 2019-02-14
BR112019000240A2 (pt) 2019-04-16
CL2019000042A1 (es) 2019-04-12
DOP2019000002A (es) 2019-03-31

Similar Documents

Publication Publication Date Title
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201809751XA (en) Egfr inhibitor compounds
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201906222WA (en) Jak1 selective inhibitors
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201909155VA (en) Ask1 inhibitor compounds and uses thereof
SG11201807784SA (en) 3-desoxy derivative and pharmaceutical compositions thereof
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201909011PA (en) Niraparib compositions
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201908393YA (en) Modulators of pcsk9 expression
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201907505TA (en) Low-viscosity, high-concentration evolocumab formulations and methods of making the same
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201805001UA (en) Method of treating influenza a
SG11201811345TA (en) Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11202000494UA (en) Drug delivery composition
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201806424TA (en) Therapeutic compounds